rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2010-6-2-185-191rpcardio-818Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯTHE MODERN ASPECTS OF CLOPIDOGREL USEСОВРЕМЕННЫЕ АСПЕКТЫ ПРИМЕНЕНИЯ КЛОПИДОГРЕЛАДанковцеваЕ. Н.DankovtsevaE. N.

к.м.н., доцент кафедры кардиологии и общей терапии 

121359 Москва, Маршала Тимошенко ул., 21

Marshall Timoshenko ul. 21, Moscow, 121359

ЗатейщиковД. А.ZateyshchikovD. A.

д.м.н., профессор кафедры кардиологии и общей терапии 

121359 Москва, Маршала Тимошенко ул., 21

Marshall Timoshenko ul. 21, Moscow, 121359

dz@bk.ruУчебно-научный медицинский центр Управления делами Президента РФРоссияTraining and Research Medical Centre of Administrative Department of the President of the Russian FederationRussian Federation20101801201662185191Copyright © Dankovtseva E.N., Zateyshchikov D.A., 20162016Данковцева Е.Н., Затейщиков Д.А.Dankovtseva E.N., Zateyshchikov D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/818

The possibilities and evidence base of clopidogrel use in clinical practice are discussed. Data about the main trails on clopidogrel efficacy in treatment and second prevention of atherothrombotic complications are presented. The results of the comparative trails of original and generic clopidogrel are also reviewed.

Рассматриваются возможности и доказательная база применения клопидогрела в клинической практике. Приводятся данные основных исследований по изучению эффективности клопидогрела при лечении и вторичной профилактике последствий атеротромбоза. Отдельно обсуждаются результаты сравнительных исследований оригинального и дженерического препаратов клопидогрела.

клопидогрелантитромбоцитарная терапияинфаркт миокардадженерикclopidogrelantiplatelet therapymyocardial infarctiongenericReferencesA randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). The CAPRIE Steering Committee. Lancet 1996;348(9038):1329-39.A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). The CAPRIE Steering Committee. Lancet 1996;348(9038):1329-39.Bhatt D.L., Marso S.P., Hirsch A.T. et al. Amplified benefit of clopidogrel versus aspirin in patients with a history of diabetes mellitus. Am J Cardiol 2002;90(6):625- 8.Bhatt D.L., Marso S.P., Hirsch A.T. et al. Amplified benefit of clopidogrel versus aspirin in patients with a history of diabetes mellitus. Am J Cardiol 2002;90(6):625- 8.Yusuf S., Zhao F., Mehta S.R. et al.; Clopidogrel in Unstable angina to prevent Re￾current Events trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N EnglJ Med 2001;345(7):494-502.Yusuf S., Zhao F., Mehta S.R. et al.; Clopidogrel in Unstable angina to prevent Re￾current Events trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N EnglJ Med 2001;345(7):494-502.Mehta S.R., Yusuf S., Peters R.J. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358(9281):527-33.Mehta S.R., Yusuf S., Peters R.J. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358(9281):527-33.Sabatine M.S., Cannon C.P., Gibson C.M. et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352(12):1179–89.Sabatine M.S., Cannon C.P., Gibson C.M. et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352(12):1179–89.Chen Z.M., Jiang L.X., Chen Y.P. et al. Addition of clopidogrel to aspirin in 45,852 patientswith acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366(9497):1607-21.Chen Z.M., Jiang L.X., Chen Y.P. et al. Addition of clopidogrel to aspirin in 45,852 patientswith acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366(9497):1607-21.Antman E.M.,HandM.,Armstrong P.W. et al.2007Focused Update oftheACC/AHA 2004 Guidelines forthe Management of Patients with ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines forthe Management of Patients with ST-Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee. Circulation 2008;117(2): 296–329.Antman E.M.,HandM.,Armstrong P.W. et al.2007Focused Update oftheACC/AHA 2004 Guidelines forthe Management of Patients with ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines forthe Management of Patients with ST-Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee. Circulation 2008;117(2): 296–329.Steinhubl S.R., Berger P.B., Mann J.T. 3rd et al. Clopidogrel for the Reduction of Events During Observation: early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288(19):2411-20.Steinhubl S.R., Berger P.B., Mann J.T. 3rd et al. Clopidogrel for the Reduction of Events During Observation: early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288(19):2411-20.Lagerqvist B.,James S.K., Stenestrand U. et al. Longterm outcomes with drug-eluting stents versus baremetal stents in Sweden. N EnglJ Med 2007;356(10):1009– 19.Lagerqvist B.,James S.K., Stenestrand U. et al. Longterm outcomes with drug-eluting stents versus baremetal stents in Sweden. N EnglJ Med 2007;356(10):1009– 19.Kastrati A., Mehilli J., Pache J. et al. Analysis of 14 trial comparing sirolimus-eluting stents with baremetal stents. N Engl J Med 2007;356(10):1030-9.Kastrati A., Mehilli J., Pache J. et al. Analysis of 14 trial comparing sirolimus-eluting stents with baremetal stents. N Engl J Med 2007;356(10):1030-9.Fraker T.D.Jr., Fihn S.D., Gibbons R.J. 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart AssociationTask Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines forthe management of patients with chronic stableangina. Circulation 2007;116(23):2762–72.Fraker T.D.Jr., Fihn S.D., Gibbons R.J. 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart AssociationTask Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines forthe management of patients with chronic stableangina. Circulation 2007;116(23):2762–72.Grines C.L., BonowR.O., CaseyD.E.Jr. et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the Ameri￾can College of Physicians. Circulation 2007;115(6):813–8.Grines C.L., BonowR.O., CaseyD.E.Jr. et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the Ameri￾can College of Physicians. Circulation 2007;115(6):813–8.Eisenstein E.L., Anstrom K.J., Kong D.F. et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297(2):159– 68.Eisenstein E.L., Anstrom K.J., Kong D.F. et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297(2):159– 68.Daemen J., Wenaweser P., Tsuchida K. et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369(9562):667– 78.Daemen J., Wenaweser P., Tsuchida K. et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369(9562):667– 78.Airoldi F., Colombo A., Morici N. et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116(7):745–54.Airoldi F., Colombo A., Morici N. et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116(7):745–54.Bhatt D.L., Fox K.A., Hacke W. et al. Clopidogrel and aspirin versus aspirin alone forthe prevention of atherosclerotic events. N EnglJ Med 2006;354(16):1706– 17.Bhatt D.L., Fox K.A., Hacke W. et al. Clopidogrel and aspirin versus aspirin alone forthe prevention of atherosclerotic events. N EnglJ Med 2006;354(16):1706– 17.Bhatt D.L., Flather M.D., Hacke W. et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral areterial disease in the CHARISMA trial. J Am Coll Cardiol 2007;49(19):1982–8.Bhatt D.L., Flather M.D., Hacke W. et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral areterial disease in the CHARISMA trial. J Am Coll Cardiol 2007;49(19):1982–8.Pache J., Kastrati A., Mehith J. et al. Clopidogrel therapy in patients undergoing coronary stenting: value of high-loading-dose regimen. Catheter Cardiovasc Interv 2002;55(4):436–41.Pache J., Kastrati A., Mehith J. et al. Clopidogrel therapy in patients undergoing coronary stenting: value of high-loading-dose regimen. Catheter Cardiovasc Interv 2002;55(4):436–41.Попонина Т.М., Попонина Ю.С., Капилевич Н.А., Ефимова Е.В. Современные подходык профилактике тромботических осложнений у больных с ост- рым коронарным синдромом без подъема сегмента ST. Болезни сердца и сосудов 2009;(4):4-9.Попонина Т.М., Попонина Ю.С., Капилевич Н.А., Ефимова Е.В. Современные подходык профилактике тромботических осложнений у больных с ост- рым коронарным синдромом без подъема сегмента ST. Болезни сердца и сосудов 2009;(4):4-9.Гринштейн Ю.И., Савченко Е.А., Филоненко И.В. и др. Зилт у пациентов с атеросклерозом коронарных артерий после аортокоронарного шунтирования. Предварительные результаты открытого, рандомизированного, сравнительного исследования ЗЕВС. Кардиоваскулярная терапия и профилактика 2008;7(6):43–9.Гринштейн Ю.И., Савченко Е.А., Филоненко И.В. и др. Зилт у пациентов с атеросклерозом коронарных артерий после аортокоронарного шунтирования. Предварительные результаты открытого, рандомизированного, сравнительного исследования ЗЕВС. Кардиоваскулярная терапия и профилактика 2008;7(6):43–9.Сироткина О.В., Богданова Е.В., Боганькова Н.А. и др. Эффективность антиагрегантной терапии клопидогрелом у пациентов, перенесших инфаркт миокарда с подъемом сегмента ST. Кардиоваскулярная терапия и профилактика 2009;8(1):51-5.Сироткина О.В., Богданова Е.В., Боганькова Н.А. и др. Эффективность антиагрегантной терапии клопидогрелом у пациентов, перенесших инфаркт миокарда с подъемом сегмента ST. Кардиоваскулярная терапия и профилактика 2009;8(1):51-5.Terpening С.An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events. JAm Board Fam Med 2009;22(1):51–6.Terpening С.An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events. JAm Board Fam Med 2009;22(1):51–6.

The authors declare that there are no conflicts of interest present.